Results
Trial
Research Area
Duration
Locations
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…
Open and enrolling
HIV (and comorbidities)
A5243: Non-US Genomic Sampling
Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…
Open and enrolling
HIV (and comorbidities)
This study is for people with HIV who have an undetectable viral load. The study will evaluate the safety and…
Active, Not Recruiting
HIV (and comorbidities)
Participants will be on study for about 101 weeks.
A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy
“Safety and Immunotherapeutic Activity of Cemiplimab in Participants with HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose…
Active, Not Recruiting
Hepatitis
Participants will be on study for up to 90 weeks (78 weeks following the last study drug infusion) with frequent safety evaluations.
You are being asked to take part in this research study because you are infected with HIV, the virus that…
Closed to accrual
HIV (and comorbidities)
Participants will be followed for 366 weeks (7 years).
In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin)…
Closed to accrual
HIV (and comorbidities)
You will be in this study for about 36 to 96 months depending on when you enroll in the study.
A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Aging with HIV may be associated with an earlier development of frailty (weakness) or disability, including difficulties in tests of…
Closed to accrual
HIV (and comorbidities)
Participants will be followed for 48 months from the date of enrollment into A5332. Based on their date of enrollment into A5332, participants may be followed between 24 to 48 months.
While antiretrovirals known as ARV’s (group of medicines used to treat HIV) have provided very effective treatment of HIV, cure…
Closed to accrual
HIV Cure
Up to 9 weeks per participant after a screening period of up to 90 days.
This is a study for people who have HIV and qualify to switch to or receive Dolutegravir containing antiretroviral therapy…
Closed to accrual
HIV (and comorbidities)
Each participant will be followed for 36 months.
This is a study to treat participants, with or without HIV, who are found to have been recently infected with…
Closed to accrual
Hepatitis
Up to 28 weeks on Step 1 and up to an additional 40 weeks if on Step 2.
This trial is in household contacts (HHC) at high risk for developing multidrug resistant tuberculosis (MDR-TB) which is an infection…
Open and enrolling
Tuberculosis
All participants will be in this study for 96 weeks.
This is a randomized study, which means, by chance, you will be in one of three groups. You have an…
Closed to accrual
Tuberculosis
24 weeks on study treatment, followed by 104 weeks follow-up, for a total length of 128 weeks